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Abstract  
Decellularized xenogenic or allogenic heart valves have been used as starter matrix for 
tissue-engineering of valve replacements with (pre-)clinical promising results. However, 
xenografts are associated with the risk of immunogenic reactions or disease transmission 
and availability of homografts is limited. Alternatively, biodegradable synthetic materials have 
been used to successfully create tissue-engineered heart valves (TEHV). However, such 
TEHV are associated with substantial technological and logistical complexity and have not 
yet entered clinical use. Here, decellularized TEHV, based on biodegradable synthetic 
materials and homologous cells, are introduced as an alternative starter matrix for guided 
tissue regeneration. Decellularization of TEHV did not alter the collagen structure or tissue 
strength and favored valve performance when compared to their cell-populated counterparts. 
Storage of the decellularized TEHV up to 18 months did not alter valve tissue properties. 
Reseeding the decellularized valves with mesenchymal stem cells was demonstrated 
feasible with minimal damage to the reseeded valve when trans-apical valve delivery was 
simulated. In conclusion, decellularization of in-vitro grown TEHV provides largely available 
off-the-shelf homologous scaffolds suitable for reseeding with autologous cells and trans-
apical valve delivery.  
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Introduction 
Worldwide, approximately 280.000 valve replacements are performed annually [1]. However, 
the quest for the ideal heart valve replacement is ongoing as current substitutes, like 
mechanical and bioprosthetic valves, lack the capability for regeneration and growth. This 
represents a substantial limitation for long-term durability, especially in children and young 
adults. Guided tissue generation and tissue engineering of heart valves are proposed to 
overcome the limitations of the current valve replacements. Both decellularized xenogenic 
and allogenic heart valves have been used as scaffold material for this purpose with pre-
clinical and clinical trials showing promising results [2-6]. However, a drawback in using 
either xenografts or homografts is the risk for an immunogenic response [7], which may 
unfavorably impact the long-term graft durability [8]. Graft decellularization is applied to 
decrease this immunological response, however, it is suggested that a number of 
inflammatory stimuli are still active within decellularized xenogenic tissue, causing graft 
failure [9]. In addition, the use of unfixed xenografts carries the risk of disease transmission, 
such as e.g. Creutzfeldt–Jakob disease [10]. The decellularized homograft (allograft) is 
therefore a safer option compared to the xenograft. Additionally, the homograft 
microstructure is favorable regarding survival, proliferation, and differentiation of reseeded 
cells [11]. However, a major limitation of homografts is their limited availability due to donor 
shortage, especially regarding small-sized valves.  
As alternative to xeno- and homografts, biodegradable synthetic materials have been 
investigated for tissue engineering [12-15]. These materials are attractive because of their 
unlimited supply, and the lack of any xenogenic disease transmission and rejection risk. After 
biodegradation of the scaffold, a completely autologous living valve can be obtained with the 
capability to adapt, remodel and grow [14].These living tissue-engineered heart valves 
(TEHV) have shown in-vitro and in-vivo functionality [11,14,16-23]. However, a common 
observation is retraction of the leaflets, resulting in valvular insufficiency [12,19,22,24-26]. As 
the observed retraction is mainly cell-mediated, cell removal of TEHV represents a strategy 
to reduce retraction of the leaflets. Upon attaining sufficient amounts of extracellular matrix 
in-vitro, removal of the cells can be realized by a decellularization procedure. 
Decellularization has been intensively investigated for xeno- and homografts [27]. Although 
this procedure has been applied to tissue-engineered arteries [28-30], it is to our knowledge, 
not applied to TEHV. In addition to reducing cell-mediated leaflet retraction, decellularization 
enables storage and subsequent off-the-shelf availability of the valve replacements. 
 
To overcome the limitations of current valve replacements and tissue-engineered solutions, 
there is a need for a widely available, unfixed, homologous valve substitute, without the loss 
of functionality due to leaflet retraction. Therefore, in this study we investigate to decellularize 
in-vitro grown TEHV based on rapidly degrading synthetic scaffolds and homologous cells. 
We tested the feasibility of this approach by demonstrating cell removal and analysis of the 
biomechanical properties and in-vitro functionality. Clinical applicability was evaluated by 
studying the effect of storage upon the tissue properties of the decellularized TEHV. These  
off-the-shelf homologous valves can be used as scaffold for guided tissue generation or be 
reseeded prior to implantation. Non-toxicity and reseeding capacity of the decellularized 
TEHV with bone-marrow mesenchymal stem cells (MSC) was investigated. In addition, the 
impact of crimping on the reseeded cells was assessed to demonstrate feasibility of the use 
of reseeded decellularized TEHV for minimally invasive valve delivery. 
 
Materials and methods 
Heart valve tissue engineering 
Tri-leaflet heart valve scaffolds (n=15) were fabricated from non-woven polyglycolic-acid 
meshes (PGA; thickness 1.0 mm; specific gravity 70 mg/cm3; Cellon, Bereldange 
Luxembourg) and coated with 1.75% poly-4-hydroxybutyrate (P4HB; MW: 1 x 106; TEPHA 
Inc., Lexington MA USA) in tetrahydrofuran (THF; Fluka (Sigma-Aldrich, St Louis MO USA)). 
Scaffolds were integrated into radially self-expandable nitinol stents (length=27mm, 
OD=25mm (n=9) or OD=30mm (n=6) when fully expanded at 37oC; pfm-AG, Köln Germany). 
Ovine vascular derived cells (previously characterized to express vimentin, SMemb, and 
hsp47, and partially α-SMA {Geemen, 2012 317 /id}), expanded in DMEM Advanced (Gibco, 
Invitrogen, Carlsbad CA USA), supplemented with 10% lamb serum (Gibco, Invitrogen), 1% 
GlutaMax (Gibco, Invitrogen), and 1% Penicillin-streptomycin (Lonza, Verviers Belgium), 
were seeded onto the stented heart valve scaffolds (1.5x106 cells/cm2, passage 6) using 
fibrin as cell carrier [13]. After seeding, scaffolds were placed into Diastolic Pulse Duplicator 
systems for culture in closed configuration [32]. The leaflets were exposed to dynamic strains 
by applying increasing transvalvular pressure differences that started from 3 mm Hg after 5 
days and build up to 15 mm Hg in the 4 following days and kept as such until the fourth 
week. TE-medium (DMEM Advanced, supplemented with 0.1% lamb serum, 1% GlutaMax, 
1% Penicillin-streptomycin, and L-ascorbic acid 2-phosphate (0.25 mg/ml; Sigma-Aldrich)) 
was replaced every 2 to 3 days. After 4 weeks of culturing, the TEHV were either 
decellularized (n=12) or analyzed directly as cell-populated controls (n=3).  
 
Decellularization 
A decellularization protocol, based on existing protocols [33,34], was applied to the in-vitro 
grown TEHV (n=12). In short, the TEHV were washed three times in PBS (Sigma-Aldrich) 
and decellularized overnight via incubation in PBS supplemented with 0.25% Triton X-100 
(Merck, Darmstadt Germany), 0.25% sodium deoxycholate (SD, Sigma-Aldrich), and 0.02% 
EDTA (Sigma-Aldrich) at 37°C. Decellularization was followed by two washing cycles in PBS. 
Subsequently, TEHV were treated with a nuclease digestion solution of 50-mM TRIS-HCl 
buffer (Tris (hydroxymethyl)-aminomethan (Merck) pH 8.0, supplemented with 100 U/ml 
Benzonase® (25 units/µl, Novagen, Madison WI USA) and 1 mmol/l of MgCl2 (Merck)) at 
37°C, to remove remaining nucleic remnants. After 5-8 hours the nuclease digestion solution 
was replaced with a nuclease digestion solution containing 80 U/ml Benzonase® and 
incubated overnight. Thereafter, the solution was replaced again by a 20 U/ml Benzonase® 
solution and incubated for 5-8 hours. The TEHV were washed twice in PBS, followed by a 
washing cycle with M-199 medium (Gibco, Invitrogen) for more than 24 hours at 4°C to 
remove cellular remnants. TEHV were washed twice in PBS to remove the medium, 
sterilized in 70% EtOH (70% ethanol absolute (VWR international S.A.S. Fontenay-Sous-
Bois, France) and 30% autoclaved ultrapure water) for 30 minutes, and again washed in 
sterile PBS. All steps were conducted under continuous shaking. Decellularized TEHV were 
used for functionality testing (n=6), stored for 18 months in fresh M-199 medium (at 4oC) 
(n=2), or reseeded with MSC (n=4). 
 
In-vitro valve performance of cell-populated- and decellularized TEHV 
Functionality of the cell-populated TEHV and decellularized TEHV was visualized in a 
custom-built valve tester [35], using a high-speed video camera (MotionScope M-5; IDT, 
Lommel Belgium). To minimize cell-mediated retraction in the cell-populated TEHV before 
testing, separation of the fused leaflets was performed within 5 minutes prior to testing. Cell-
populated (n=3, ID=23mm) and decellularized (n=4, ID=23mm; n=2, ID=28mm) TEHV were 
exposed to pulmonary conditions for 20 minutes (peak systolic blood pressure of 30 mmHg; 
end-diastolic blood pressure of 10 mmHg; 72 bpm). The resulting flow and pressure profiles 
were measured using flow (Transonic, Ithaca NY USA) and pressure sensors (Becton 
Dickinson, Temse Belgium). To assess prolonged endurance of the decellularized TEHV, the 
exposure to pulmonary conditions was continued for 24 hours (n=1, OD=23mm; n=2, 
OD=28mm). The cell-populated TEHV showed too much regurgitation to perform endurance 
tests. Measures for regurgitation, effective orifice area (EOA, expressed in percentage of the 
valve root surface area in order to compare valves with different diameters), and peak 
systolic pressure gradient were obtained for each tested valve after 20 minutes and 24 hours 
(if applicable) by averaging these parameters over 10 cycles and compared to those of a 
porcine aortic bioprosthesis (n=1; ID=23mm; Epic Valve, St. Jude Medical Inc, St. Paul MN 
USA). 
 
Reseeding decellularized TEHV with mesenchymal stem cells (MSC)  
MSC isolation, characterization, and differentiation potential 
MSC were isolated from bone marrow of adult sheep by density gradient using standardized 
protocols [36]. The mononuclear cell fraction was plated out in expansion medium (α-MEM 
(Gibco, Invitrogen), supplemented with 10% calf serum (Gibco, Invitrogen), 2 mM L – 
Glutamin (Gibco, Invitrogen), and 1% Penicillin-streptomycin (Lonza)). After 72 hours, the 
non-adherent cells were discarded and adherent cells were washed gently with medium, 
cultured for about 14 days, and subsequently stored in liquid nitrogen. One week prior to 
seeding MSC were thawed and expanded further in growth medium (MSC-medium; α-mem 
(Gibco, Invitrogen), supplemented with 10% lamb serum (Gibco, Invitrogen), 1% GlutaMax 
(Gibco, Invitrogen), and 1% Penicillin-streptomycin (Lonza)), which was replaced twice per 
week. 
Cells (passage 2 and 10) were FACS analyzed for MSC cell surface markers CD29, CD44, 
CD166,  Stro-4, CD14, CD45, and CD31 [37].  To induce differentiation into adipocytes and 
osteocytes, ovine MSC were plated at 1000 cells per cm2 in multiwall plates. For adipogenic 
differentiation the basic medium DMEM (Gibco, Invitrogen) was supplemented with 1 µM 
dexamethasone (Sigma-Aldrich), 120 µM indomethacin (Sigma-Aldrich), 10 µg/ml insulin 
(Sigma-Aldrich), 2 mM L-glutamine (Gibco, Invitrogen) and penicillin/streptomycin (Gibco, 
Invitrogen). The osteogenic induction medium contained DMEM supplemented with 10 mM 
β- glycerophol-2-phosphate (Sigma-Aldrich), 50µM ascorbic acid-2-phosphate (Sigma-
Aldrich), 10µm dexamethasone, 2 mM L-glutamine, penicillin/ streptomycin and 10% FCS 
(Biowest, France). The chondrogenic differentiation was evaluated in a 15 ml conical tube 
with 2x105 cells/ml in DMEM medium supplemented with 2 mM L-glutamine, 1% FCS, 10 
ng/ml TGF-β (Peprotech, USA), 50 µM ascorbic acid and 0.5 µg/ml insulin. During the total 
differentiation period of 21days all induction media were replaced three times a week. The 
differentiation cultures were harvested after 21 days, washed in PBS and fixed in 4% 
Formalin for 1 h before histological analyses. For histological evaluation cells were stained 
with Oil Red-O (to detect lipid vacuoles), Alizarin Red S (to detect calcium deposits) and 
Toluidin blue staining (to detect cartilage-specific proteoglycan synthesis).  
Reseeding decellularized TEHV with MSC 
To show feasibility of the decellularized TEHV as living implant, decellularized TEHV (n=4) 
were reseeded with ovine bone marrow derived mesenchymal stem cells (MSC; 0.1x106 
cells/cm2, passage 5). In order to create a confluent layer of MSC on the valves, the 
reseeded valves were cultured in MSC-medium under static conditions for 2 to 3 days until 
further analysis. 
Crimping and cell viability of reseeded decellularized TEHV 
To demonstrate the potential of the living TEHV for minimally invasive implantation 
procedures, simulation of the necessitated crimping procedure was performed with the 
reseeded decellularized TEHV (n=3), as described previously [22]. After simulation of the 
crimping procedure cell viability was assessed and compared to the non-crimped control 
(n=1) by whole-mount staining with cell tracker green CMFDA (CTG; Molecular Probes, the 
Netherlands) and propidium iodine (PI; Molecular Probes, the Netherlands), as described 
previously [38]. Visualization was performed with a 2-photon confocal microscope (Laser 
Scanning Microscope 510 META NLO, Zeiss, Germany) to observe living cells in green and 
dead cells in red. 
 
Qualitative and quantitative valve tissue analyses 
Histology and SEM 
All TEHV (n=15) were evaluated qualitatively by histology. Representative pieces of TEHV 
were formalin-fixed and either embedded into paraffin and sectioned at 7 µm or snapfrozen 
and sectioned at 10 µm.  The paraffin sections were stained with Haematoxylin and Eosin 
(H&E, Sigma-Aldrich) to visualize general tissue morphology and presence of cells, with 
Picrosirius Red for collagen structure, and with DAPI to assess the presence of cell nuclei. 
Frozen sections of the cell-populated and decellularized TEHV were stained with FITC-
labeled phalloidin (1:200; Sigma-Aldrich) and DAPI to visualize (removal of) F-actin and 
nuclei, respectively.  The H&E and Picrosirius Red staining were visualized by normal light 
microscopy. The Picrosirius Red staining was additionally visualized by polarized light 
microscopy. DAPI and F-actin stainings were visualized by fluorescence microscopy. Tissue 
samples of the reseeded decellularized TEHV were fixed in 2% glutaraldehyde (Sigma, USA) 
and sputtered with platin in order to examine confluency of the seeded cells by SEM.  
DNA and extracellular matrix analyses 
Cell-populated (n=3), decellularized (n=4), and stored decellularized (n=2) TEHV were 
analyzed quantitatively for total amount of DNA, as an indicator for cell number, 
glycosaminoglycans, and hydroxyproline, as an indicator for collagen. For each valve, two 
samples per leaflet were analyzed. Hence, all valves contained 6 individual measurements, 
which were averaged to represent an average value for each valve. The amount of DNA was 
measured using the commercially available Quant-iTTM Picogreen® dsDNA kit (Molecular 
Probes, Invitrogen). The glycosaminoglycans content was determined using a modified 
version of the protocol described by Farndale et al. [39] and a standard curve prepared from 
chondroitin sulphate from shark cartilage (Sigma Aldrich) in addition to the samples. Briefly, 
40 µl of diluted sample (without addition of chondroitin AC lyase, chondroitin ABC lyase and 
keratanase) was pipetted into a 96-well plate in duplicate. Subsequently, 150 µl 
dimethylmethylene blue (46 µM dimethylmethylene blue, 40.5 mM glycin, 40.5 mM NaCl, pH 
3.0) was added and absorbance was measured at 540 nm. Hydroxyproline content was 
determined according to the protocol described by Huszar et al. [40] and a standard curve 
prepared from trans-4-hydroxyproline (Sigma Aldrich). The amounts of DNA, 
glycosaminoglycans, and hydroxyproline were expressed per mg dry weight of tissue.  
Mechanical analyses 
The mechanical properties of the leaflets of cell-populated (n=3), decellularized (n=4), and 
stored decellularized (n=2) TEHV were determined by uniaxial tensile tests. Three strips in 
the circumferential and 4 strips in the radial direction (width=2.9±0.4mm) were cut from the 
leaflets from each TEHV. Stress-strain curves were obtained using a uniaxial tensile tester 
(Kammrath & Weiss GmbH, Dortmund Germany), equipped with a 20N load cell and all 
samples were tested at identical strain rate (150µm/s for strips 9 mm in length and 100µm/s 
for strips 6 mm in length). The ultimate tensile strength (UTS), as measure for tissue 
strength, was defined as the maximum stress value in the stress-strain curve. The Youngs 
modulus, as measure for tissue stiffness, was determined as the slope in the linear region of 
the stress-strain curve at large strains. The obtained values for tissue strength and stiffness 
were averaged for each valve. 
 
Statistics 
Measurements are presented as the mean ± standard error of the mean (SEM). One-way 
ANOVA (post hoc Bonferroni) was used to determine the differences between the groups of 
valves with respect to functionality parameters, extracellular matrix contents and mechanical 
properties. STATGRAPHICS software (Statistical Graphics corp., USA) was used for 
statistical analysis with p<0.05 considered as statistically significant.  
 
Results 
Macroscopic valve appearance 
The macroscopic appearance of the cell-populated TEHV revealed thin, shiny tissue 
formation in the wall and leaflets with no visual changes upon decellularization (Figure 1A, D, 
and G). After separation of the leaflets, the cell-populated TEHV demonstrated leaflet 
retraction (Figure 1B). In the decellularized TEHV and the MSC-reseeded decellularized 
TEHV retraction of the leaflets was minimal (Figure 1E and H, respectively). After exposure 
to pulmonary conditions in the valve tester for 20 minutes, the leaflets of the cell-populated 
TEHV had completely retracted (Figure 1C), while the decellularized leaflets did not show 
retraction after 24 hours of exposure to pulmonary conditions (Figure 1F). The crimping 
procedure to simulate minimally invasive valve delivery is demonstrated in Figure 1I. 
 
In-vitro valve performance 
Opening and closing behavior of the TEHV was improved after decellularization (Figure 2), 
though some prolapse of the leaflets was observed in the decellularized TEHV (Figure 2A). 
In contrast, closure of the cell-populated valve leaflets was hampered by retraction of the 
leaflets (Figure 2B). The cell-populated TEHV demonstrated 30±9% regurgitation, which 
reduced by decellularization to 15±2% (p<0.05) and remained stable at 18±2% after 24 hours 
endurance testing. The effective orifice area (EOA, expressed in percentage of the valve root 
surface area) increased from 53±8% for the cell-populated TEHV to 66±3% for the 
decellularized TEHV (p<0.05). The EOA of the decellularized TEHV remained stable at 
61±4% after 24 hours endurance testing. The peak systolic pressure gradient for the cell-
populated TEHV was 17±2 mm Hg and was reduced to 10±1 mm Hg by decellularization 
(p<0.05), remaining stable at 8±1 mm Hg after 24 hours endurance testing. For comparison, 
the average values for the porcine aortic valve bioprothesis tested at similar conditions were 
4±1% regurgitation and an EOA of 40±0% (both significantly lower compared to the 
decellularized TEHV, p<0.05). The peak systolic pressure gradient was 18±1 mm Hg 
(significantly higher compared to the decellularized TEHV, p<0.05).  
 
Qualitative and quantitative valve tissue properties 
Histological appearance 
Histology of the cell-populated TEHV revealed cellular tissue formation (Figure 3A-C) with 
higher cellularity in the outer tissue layers, which was most clearly observed in the wall. 
Abundant amounts of cross-linked collagen were detected in the leaflets (Figure 3D and E) 
and the wall. After decellularization, no cells were detected (Figure 3F-H), while the structure 
and deposition of the collagen in the leaflets (Figure 3I and J) and the wall were maintained. 
Storage of the decellularized TEHV for 18 months did not affect the histological appearance 
(data not shown). 
 
DNA and extracellular matrix 
The results of the quantitative tissue analyses are presented in Figure 5. Decellularization of 
the TEHV revealed a significant reduction (over 99%) in the amount of DNA. Although the 
amount of glycosaminoglycans was significantly reduced after decellularization, no 
differences with respect to the amount of hydroxyproline (representative for 10% of the 
amount of collagen [41]) were observed. Storage of the decellularized valves did not affect 
tissue matrix composition. Compared to native valves, the cell-populated TEHV showed 28% 
of the DNA amount, 74% of collagen amount, and 94% of the amount of glycosaminoglycans 
measured in native ovine valve leaflets [22]. 
 
Mechanical properties 
No significant differences were observed in mechanical behavior of the strips in radial 
direction compared to circumferential direction in both the cell-populated and decellularized 
TEHV. Therefore, these values were pooled. The decellularized and stored decellularized 
TEHV showed a shift of the stress-strain curves to the left when compared to the cell-
populated TEHV (Figure 5A). The Youngs modulus of the decellularized TEHV was 
increased compared to the cell-populated TEHV (Figure 5B). The decellularization procedure 
did not affect tissue strength (UTS), but reduced the thickness of the TEHV (Figure 5B). 
Storage of the decellularized TEHV for 18 months did not significantly change the 
mechanical properties compared to the decellularized TEHV (Figure 5B). 
 
MSC characterization, differentiation, and reseeding of decellularized TEHV 
The bone marrow derived population of cells exhibited an immunophenotype associated with 
cultured MSC (CD29+/CD44+/CD166+/ Stro-4+/CD14+-/CD45-/CD31-; data not shown). 
Moreover, differentiation potential of the cells was demonstrated by differentiation into 
osteogenic, chondrogenic, and adipogenic cell lineages (Figure 6A, B, and C, respectively). 
After reseeding the decellularized TEHV with MSC, a confluent layer of cells was 
demonstrated on the leaflets and wall by histology and SEM (Figure 6D-I). 
 
Viability and crimping of reseeded decellularized TEHV  
The confluent cell layer was demonstrated to consist of viable cells (Figure 7A), which 
remained viable after the simulated crimping procedure (Figure 7B), although some spots of 
local damage were observed (Figure 7B insert). 
 
  
Discussion 
In this study, we investigated the feasibility of a  off-the-shelf tissue engineered homologous 
heart valve concept providing unrestricted availability and minimal risk for immunogenic 
reactions or disease transmission. Our approach was to decellularize in-vitro grown TEHV, 
based on rapidly degrading synthetic scaffolds, in order to create starter matrices for guided 
tissue generation and tissue engineering as an alternative to xeno-and homografts. 
Complete cell removal was demonstrated histologically and biochemically. The effects of 
decellularization on extracellular matrix content, biomechanical properties, and in-vitro valve 
functionality were assessed by comparisons to cell-populated TEHV. Further, the effect of 
storage on the tissue properties and the reseeding feasibility of the decellularized TEHV 
were evaluated as well as the potential of reseeded decellularized TEHV for minimally 
invasive valve delivery procedures. 
 
Cell-mediated traction is functional in ensuring the development of a desirable, highly aligned 
extracellular matrix in tissue-engineered cardiovascular substitutes [23,26,32,42,43]. 
However, sustained traction forces can result in undesirable retraction of the leaflets, 
resulting in valvular regurgitation [12,19,22,24,26]. Although it has been suggested to avoid 
valvular insufficiency by creating longer leaflets and a larger coaptation areas [26,44], 
engineering bi-leaflet valves instead of tri-leaflet valves [23,44], or applying a biodegradable 
support material within the fibrin scaffold [19], a sustained solution to control these traction 
forces is still lacking. This study shows that decellularization of the TEHV effectively reduces 
the retraction of the leaflets in-vitro.  
 
The efficiency of cell removal, as well as preservation of the matrix integrity is highly 
dependent on the decellularization method used.  Cell remnant removal is necessary, as the 
presence of dead cells potentially lead to inflammation and or calcification in-vivo [45]. In the 
present study, we choose to decellularize our TEHV with sodium deoxycholate (SD). Various 
studies showed that SD-based treatments are more efficient in cell removal, while 
maintaining matrix integrity and mechanical properties when compared to decellularization 
with Trypsin [8,46-48]. The use of SD is preferred above sodium dodecylsulfate (SDS) [8,49] 
and was used to produce xenogenic valve replacements that functioned properly in sheep 
[50]. Furthermore, an increased reseeding potential is documented for SD-treated 
extracellular matrix, when compared to SDS specimens [46]. The SD-treatment is often 
applied in combination with Triton X-100 [8,46], as decellularization using SD alone is not 
always satisfactory [50]. Therefore, we choose to include the use of Triton-X 100. The 
presence of small amounts of cellular antigens is described to be insufficient to elicit the type 
of pro-inflammatory or immune response that could adversely affect biological scaffold 
remodeling [51]. On the contrary, it is suggested that a low level expression of the α-gal-
epitope has the potential to initiate an inflammatory response, leading to graft failure [9]. 
When translating the approach of the current study to human, the potential inflammatory 
response due to expression of the α-gal-epitope is avoided by using homologous cells. 
Nevertheless, with respect to calcification, complete cell removal should be pursued, as 
residual cells and cell remnants within the matrix might induce calcification [45]. The protocol 
used for decellularization of the TEHV in this study demonstrated to remove over 99% of the 
cellular material. Although serum nucleases can be applied to further reduce the DNA 
amounts in detergent pretreated tissues [29], the clinical efficacy of commercially available 
materials has been claimed despite small amounts of remaining DNA [51].  
 
Preservation of collagen integrity in the decellularized valve replacements was demonstrated 
by histology. Remarkably, although not significant, biochemical analysis indicated a trend 
towards increased collagen amounts after decellularization, which has been observed 
previously by others [52]. This (non-significant) increase in collagen in the decellularized 
TEHV compared to the cell-populated TEHV is assumed to originate from the loss of cells 
and glycosaminoglycans, and therewith the relative decrease in the dry weight of the sample. 
In the current study, we observed a reduction of one-third of the amount of 
glycosaminoglycans after decellularization. Although Grauss and colleagues [53] observed 
an almost complete washout of glycosaminoglycans after decellularization with Triton-X, 
most other studies investigating decellularization of biological matrices did not study the 
effect on glycosaminoglycans. Because glycosaminoglycans appear to play a significant role 
in shock absorption, tissue elasticity, and prevention of calcification [54], replenishment of the 
lost compounds should be pursued in-vivo to enhance valvular durability.  As a mature 
elastic network has not yet been detected in our cell-populated TEHV, the effect of 
decellularization on the elastin network was not explored. However, the formation of an 
elastic network in the TEHV is of particular importance for the biomechanical behavior of the 
valve [55] and is subject of current research.   
 
The decellularized valve leaflets were thinner compared to the cell-populated leaflets, which 
cause is twofold. Firstly, the observed reduction of glycosaminoglycans after decellularization 
is likely to be associated with a loss in water content. Secondly, the cell-populated leaflets 
were most probably thickened due to cell-mediated retraction directly after separation of the 
merged leaflets. The retraction in the cell-populated leaflets may also explain the observed 
shift to the left of the linear part of the stress-strain curve after decellularization. Similar shifts 
in stress-strain curves were observed for native decellularized tissues [28]. Elongation of the 
cell-populated samples before testing to their original length before retraction is hypothesized 
to result in the same shift as observed for the decellularized samples.  
 
Tissue strength of the leaflets was not affected by the decellularization procedure. The tissue 
stiffness was increased, but did not negatively affect valve functionality of the decellularized 
TEHV. Moreover, peak systolic pressure gradients were decreased in the decellularized 
TEHV, while the EOA was increased, probably due to reduced thickness of the leaflets. 
Additionally, reduced leaflet retraction after decellularization had a beneficial effect on the 
regurgitation. Compared to the cell-populated TEHV, the decellularized TEHV showed 
significantly reduced regurgitation that remained stable up to 24 hours endurance testing. 
Closure of the cell-populated TEHV was hampered by cell-mediated retraction of the leaflets 
and, therefore, endurance tests of these valves have not been performed. Although closure 
of the leaflets was significantly improved by decellularization, regurgitation was still observed, 
caused by subtle leaflet prolapse. Enlargement of the coaptation area of the leaflets is 
proposed to avoid the observed prolapse and is currently under investigation. The EOA and 
peak systolic pressure gradient of the decellularized TEHV were higher and lower, 
respectively, than those of the porcine aortic bioprosthesis. Though, it should be noted that 
the aortic bioprosthesis did not function satisfactory at pulmonary conditions.  
 
Growth and remodeling of the valve replacement in-vivo requires a living tissue and, 
therewith, (re)population of the acellular tissue with cells. Still, it is unclear whether there is a 
need for recellularization prior to implantation, or whether circulating cells or cells from 
adjacent tissues may repopulate the scaffold in-vivo [56,57]. Engineered decellularized 
tissues may be superior for cellular migration compared to decellularized native tissues, due 
to a lack of prominent elastin barriers and a less mature collagen structure [28,52]. Long-
term animal experiments have to clarify the need for in-vitro preseeding and are necessary to 
demonstrate growth and remodeling potential. Nevertheless, the feasibility of using 
decellularized TEHV as living implant was demonstrated by in-vitro reseeding with bone 
marrow derived mesenchymal stem cells (MSC). MSC are attractive candidates and 
successfully used to reseed decellularized matrices [11,58]. Moreover, MSC show a 
remarkable similarity in phenotype compared to valvular interstitial cells [59], demonstrate 
anti-thrombogenic [60], and immunosuppressive properties [61], and suitability for utilization 
in routine clinical practice, due to their ease of accessibility, handling and their use for 
multiple recipients [62]. Additionally, both the anti-thrombogenic properties of the MSC [60] 
and the ability to stimulate in-vivo endothelization [63] overcome the necessity of preseeding 
with endothelial cells.  
After reseeding the decellularized TEHV, a confluent cell layer was observed within 3 days, 
without cell-mediated retraction of the leaflets. By reseeding the valves with MSC we aim for 
in-vivo recellularization with recipient cells [64]. Reseeded or not, we hypothesize that leaflet 
retraction of the decellularized TEHV will not re-occur in-vivo, as the contractile 
myofibroblasts are removed and should be replaced by cells with a more quiescent and less 
contractile phenotype. Moreover, in-vivo leaflet shortening has been shown to be prevented 
by hemodynamic loading [65]. Nevertheless, animal experiments are mandatory to elucidate 
whether leaflet retraction will not re-occur in-vivo.   
 
Storage of the valves for 18 months did not affect the collagen structure, extra cellular matrix 
composition or the mechanical behavior. These results support the potential use of 
decellularized TEHV to serve as off-the-shelf valve replacements.  Besides, clinical 
application for guided tissue generation and tissue engineering is attractive as the 
decellularized TEHV are suitable for minimally invasive implantation techniques. These  
heart valve replacement procedures represent an attractive alternative treatment option for 
patients with valvular heart disease and will likely have a major impact on the management 
of these patients over the next several years [66]. A perquisite for minimally invasive 
implantation techniques is crimping of the valve to fit the delivery device. In the case of a 
living implant, the crimping could be harmful to the cells. Therefore, simulation of the 
necessitated crimping procedure was evaluated for the reseeded decellularized TEHV. The 
observed cell damage due this crimping procedure was small and only locally. Therefore, the 
crimping is hypothesized not to affect the proposed in-vivo recruitment of cells by the MSC.  
 
Conclusion 
Here we demonstrate that decellularization of TEHV is feasible with efficient cell removal and 
preservation of collagen and tissue strength. By creating TEHV from rapid degrading 
synthetic scaffolds and homologous cells we avoid the risks for xenograft-specific immune 
responses or disease transmission. Moreover, decellularization enables on-the-shelf storage 
of the in-vitro grown TEHV and strongly reduces cell-mediated retraction, thereby improving 
valve performance. Decellularized homologous TEHV have the potential to serve as largely 
available off-the-shelf scaffolds without risk for xenogenic disease transmission. These  
scaffolds can be used as starter material for guided tissue generation and tissue engineering 
and potentially serve as an alternative to xeno-and homografts.  
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Figure legends  
 
Figure 1: Macroscopic appearance of the cell-populated TEHV (A-C), decellularized (D-
G), and reseeded TEHV (H-J). The macroscopic appearance of the cell-populated TEHV (A) 
was not affected by decellularization (D) and revealed thin, shiny tissue formation in the wall 
and leaflets (G; ventricular surface of the valve leaflets). Retraction of the leaflets of the cell-
populated TEHV (B) is seen immediately after separation of the leaflets, which is absent in 
the decellularized TEHV (E) and did not re-occur after reseeding with MSC (H). After 20 
minutes exposure to pulmonary conditions, the leaflets of the TEHV were completely 
retracted (C), while the decellularized leaflets do not show this retraction even after 24 hours 
of exposure to pulmonary conditions (F). In order to test their potential for minimally invasive 
implantation, the reseeded valves were crimped (I) before analyses. 
 
Figure 2: In-vitro functionality of cell-populated and decellularized TEHV. (A) After 
decellularization the TEHV showed improved opening and closing behavior when exposed to 
pulmonary conditions, although some prolapse of the leaflets (indicated by black arrows) was 
observed. (B) Closure of the cell-populated valve leaflets was hampered by retraction of the 
leaflets.  
 
Figure 3: Histology of the cell-populated (A-E) and decellularized (F-J) TEHV. 
Haematoxylin and Eosin staining (H&E; A, B, F, G), Phalloidin and DAPI staining (C and H), 
Picrosirius red staining visualized by transmitted light (D and I), and Picrosirius red staining 
visualized by polarized light (E and J). Overview of wall and leaflet of cell-populated TEHV 
(A) indicating locations of images B-E. Overview of wall and leaflet of decellularized TEHV 
(F) indicating locations of images G-J. Before decellularization, cellular tissues (A, B, and C) 
contained abundant amounts of collagen (D and E) and F-actin (C). After decellularization, 
the leaflets demonstrated preserved structural integrity (F and G) and collagen (I and J), but 
no F-actin (H) or nuclei (F, G, and H). Scale bars in A and F represent 1 mm; Scale bars in 
B-E and G-J represent 200µm. 
 
Figure 4: Amounts of glycosaminoglycans, hydroxyproline, and DNA in the leaflets of 
the cell-populated, decellularized, and stored decellularized TEHV. Values are 
represented as mean values ± SEM. The amount of DNA and glycosaminoglycans (GAG) 
was significantly reduced in the decellularized and stored decellularized TEHV compared to 
the cell-populated TEHV (**p<0.01 and *p<0.05, respectively). No differences with respect to 
the amount of hydroxyproline (Hyp; representative for 10% of the amount of collagen [41]) 
were observed in the decellularized and stored decellularized TEHV compared to the cell-
populated TEHV. Storage of the decellularized TEHV did not affect the amounts of DNA, 
glycosaminoglycans (GAG), or hydroxyproline (Hyp). 
 
Figure 5: Mechanical properties of the leaflets of the cell-populated, decellularized and 
stored decellularized TEHV. Values are represented as mean values ± SEM (A) Typical 
examples of stress-strain curves of uniaxial tensile tests. (B) Neither the decellularization 
procedure nor the storage period significantly affected the tissue strength (UTS) or stiffness 
(Youngs modulus). The thickness of the decellularized and stored decellularized TEHV was 
reduced compared to the cell-populated TEHV (* p<0.05). 
 
Figure 6: MSC differentiation and reseeding of the decellularized TEHV. Differentiation 
potential of the MSC was demonstrated by differentiation into osteogenic (A; Alizarin Red S 
staining), chondrogenic (B; Toluidin blue staining), and adipogenic (C; Oil Red-O staining) cell 
lineages. After reseeding the decellularized TEHV, Haematoxylin and Eosin (D) and DAPI 
staining (E and F) confirmed the attachment of cells, which formed a confluent layer after 3 
days, as demonstrated by SEM (G-I). Scale bars in: A and C represent 25µm; B represents 
100µm; D-F represent 200µm; G-I represent 1mm, 100µm, and 10µm, respectively. 
 
Figure 7: Viability of the reseeded decellularized TEHV before and after crimping. A 
confluent layer of living cells (green) was observed on the reseeded decellularized TEHV (A), 
which was still viable after crimping of the valves (B). Small clusters of dead cells (red, 
indicated by white arrows) were observed due to the crimping of the valves (enlarged in 
inserted image of B).  Scale bars in A and B represent 200µm. 
 
 
 








